IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma
Diffuse intrinsic pontine glioma (DIPG) is a universally fatal childhood [...]
Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species
In complex, highly unstable genomes such as in osteosarcoma, targeting [...]
Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. [...]
Combination therapy design for maximizing sensitivity and minimizing toxicity
Design of personalized targeted therapies involve modeling of patient sensitivity [...]
Target Inhibition Maps Based on Responses to Kinase Inhibitors
The prediction of tumor sensitivity to targeted drugs remains a [...]
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood cancer. [...]
A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent
Diffuse intrinsic pontine gliomas (DIPGs) represent a particularly lethal type [...]
An Integrated Approach to Anti-Cancer Drug Sensitivity Prediction
A framework for design of personalized cancer therapy requires the [...]
Inference of dynamic biological networks based on responses to drug perturbations
Drugs that target specific proteins are a major paradigm in [...]
Rb1 loss modifies but does not initiate alveolar rhabdomyosarcoma
Alveolar rhabdomyosarcoma (aRMS) is a myogenic childhood sarcoma frequently associated [...]